Results 141 to 150 of about 22,545,234 (252)
This comprehensive review delivers an engineering‐centric analysis of microfluidic molecular diagnostic chips, breaking them down into foundational modules from fluid manipulation to bio‐sensing. Beyond chip design, it evaluates sample‐to‐answer integration strategies and commercial readiness levels.
Donghoon Koo +7 more
wiley +1 more source
CD200 Expression in Folliculotropic Mycosis Fungoides Emerging During Dupilumab Treatment
ABSTRACT Folliculotropic mycosis fungoides (FMF) or mycosis fungoides with folliculotropism (MF‐F) is increasingly recognized in patients initially diagnosed with atopic dermatitis (AD) who subsequently worsen during dupilumab therapy. We report a case of FMF that became clinically apparent after dupilumab treatment.
Mai Tamaki +9 more
wiley +1 more source
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam +7 more
wiley +1 more source
Interferon Alfa in the treatment of B-cell chronic lymphocytic leukemia [PDF]
Knauf, W. U. +10 more
core +1 more source
Background Mediastinal lymphoma in feline leukaemia virus (FeLV)‐positive cats is associated with a poor prognosis, and therapeutic options may be limited when adequate disease control is not achieved with chemotherapy. The efficacy of radiation therapy in this setting has not been established.
A Uno, T Hasegawa, T Mori
wiley +1 more source
Summary Microbial metabolites are key regulators of host immunity, yet their functional impact in chronic lymphocytic leukaemia (CLL) remains unclear. Following up on our earlier observations of microbiome dysbiosis in CLL, we performed predictive metabolic profiling based on 16S ribosomal RNA (rRNA) sequencing of oral and stool samples collected from ...
Monika Szelest +15 more
wiley +1 more source
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
The expanding role of bendamustine in chronic lymphocytic leukemia
Kruti Sheth Nair, Chaitra Ujjani Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA Abstract: As the most prevalent form of adult leukemia, chronic lymphocytic leukemia (CLL) affects thousands of patients ...
Nair KS, Ujjani C
core
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz +45 more
wiley +1 more source

